Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dan G Duda

Showing results (171-180 of 261) with videos related to

Pageof 27
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 19, 2024
PEARL: A Phase Ib/II Biomarker Study of Adding Radiation Therapy to Pembrolizumab Before Neoadjuvant Chemotherapy in Human Epidermal Growth Factor Receptor 2-Negative Breast CancerAlice Y Ho, Stephen Shiao, Samantha A Kobald, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 14, 2022
A Phase I Trial of TB-403 in Relapsed Medulloblastoma, Neuroblastoma, Ewing Sarcoma, and Alveolar RhabdomyosarcomaGiselle Saulnier-Sholler, Dan G Duda, Genevieve Bergendahl, et al.
Molecular Therapy Oncolytics|August 26, 2020
Oncolytic Virus with Attributes of Vesicular Stomatitis Virus and Measles Virus in Hepatobiliary and Pancreatic CancersBolni Marius Nagalo, Camilo Ayala Breton, Yumei Zhou, et al.
Cancer Research|October 15, 2009
Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancerLei Xu, Dan G Duda, Emmanuelle di Tomaso, et al.
Hepatology (Baltimore, Md.)|December 23, 2014
CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in miceYunching Chen, Rakesh R Ramjiawan, Thomas Reiberger, et al.
Plos One|June 16, 2012
Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancerJeffrey A Meyerhardt, Marek Ancukiewicz, Thomas A Abrams, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 22, 2015
Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancerRebecca S Heist, Dan G Duda, Dushyant V Sahani, et al.
Nature Communications|December 8, 2025
Inhibiting B cells enhances the efficacy of STING agonism or immune checkpoint blockade in hepatocellular carcinomaXin Liu, Zelong Liu, Chengzhan Zhu, et al.
Cancers|November 27, 2021
Changes in Blood Biomarkers of Angiogenesis and Immune Modulation after Radiation Therapy and Their Association with Outcomes in Thoracic MalignanciesEleni Gkika, Sonja Adebahr, Anton Brenner, et al.
International Journal of Radiation Oncology, Biology, Physics|June 23, 2009
Radiation Therapy Oncology Group translational research program stem cell symposium: incorporating stem cell hypotheses into clinical trialsWendy A Woodward, Robert G Bristow, Michael F Clarke, et al.
Pageof 27

Showing results (171-180 of 261) with videos related to

Sort By:
Pageof 27
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 19, 2024
PEARL: A Phase Ib/II Biomarker Study of Adding Radiation Therapy to Pembrolizumab Before Neoadjuvant Chemotherapy in Human Epidermal Growth Factor Receptor 2-Negative Breast CancerAlice Y Ho, Stephen Shiao, Samantha A Kobald, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 14, 2022
A Phase I Trial of TB-403 in Relapsed Medulloblastoma, Neuroblastoma, Ewing Sarcoma, and Alveolar RhabdomyosarcomaGiselle Saulnier-Sholler, Dan G Duda, Genevieve Bergendahl, et al.
Molecular Therapy Oncolytics|August 26, 2020
Oncolytic Virus with Attributes of Vesicular Stomatitis Virus and Measles Virus in Hepatobiliary and Pancreatic CancersBolni Marius Nagalo, Camilo Ayala Breton, Yumei Zhou, et al.
Cancer Research|October 15, 2009
Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancerLei Xu, Dan G Duda, Emmanuelle di Tomaso, et al.
Hepatology (Baltimore, Md.)|December 23, 2014
CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in miceYunching Chen, Rakesh R Ramjiawan, Thomas Reiberger, et al.
Plos One|June 16, 2012
Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancerJeffrey A Meyerhardt, Marek Ancukiewicz, Thomas A Abrams, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 22, 2015
Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancerRebecca S Heist, Dan G Duda, Dushyant V Sahani, et al.
Nature Communications|December 8, 2025
Inhibiting B cells enhances the efficacy of STING agonism or immune checkpoint blockade in hepatocellular carcinomaXin Liu, Zelong Liu, Chengzhan Zhu, et al.
Cancers|November 27, 2021
Changes in Blood Biomarkers of Angiogenesis and Immune Modulation after Radiation Therapy and Their Association with Outcomes in Thoracic MalignanciesEleni Gkika, Sonja Adebahr, Anton Brenner, et al.
International Journal of Radiation Oncology, Biology, Physics|June 23, 2009
Radiation Therapy Oncology Group translational research program stem cell symposium: incorporating stem cell hypotheses into clinical trialsWendy A Woodward, Robert G Bristow, Michael F Clarke, et al.
Pageof 27